Drug General Information
Drug ID	D0WK0P
Former ID	DIB009011
Drug Name	Topiroxostat
Synonyms	FYX-051; Xanthine oxidoreductase inhibitor (oral, gout), Fuji Yakuhin
Drug Type	Small molecular drug
Indication	Gout [ICD9: 274.00274.1274.8274.9; ICD10:M10]		Phase 2	[525044]
Company	Fuji Yakuhin Kogyo Co Ltd
Structure		Download 2D MOL 3D MOL
Formula	C13H8N6
Canonical SMILES	c1(cc(ccn1)c1n[nH]c(n1)c1ccncc1)C#N
PubChem Compound ID	5288320
Target and Pathway
Target(s)	Xanthine dehydrogenase/oxidase	Target Info	Inhibitor	[532545]
BioCyc Pathway	Purine nucleotides degradation
	Urate biosynthesis/inosine 5'-phosphate degradation
	Guanosine nucleotides degradation
	Adenosine nucleotides degradation
	Retinoate biosynthesis II
KEGG Pathway	Purine metabolism
	Caffeine metabolism
	Drug metabolism - other enzymes
	Metabolic pathways
	Peroxisome
PANTHER Pathway	Adenine and hypoxanthine salvage pathway
	Purine metabolism
PathWhiz Pathway	Caffeine Metabolism
	Purine Metabolism
Reactome	Purine catabolism
WikiPathways	Oxidative Stress
	Effects of Nitric Oxide
	Metabolism of nucleotides
	Selenium Micronutrient Network
References
Ref 525044	ClinicalTrials.gov (NCT02327754) Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout. U.S. National Institutes of Health.
Ref 532545	QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.